Plus a Cuban-vs-Arnold faceoff, a super-cheap biosimilar, and a little NCAA hockey talk
Plus a story about a 340B robot and a 340B analysis that is equal parts intriguing and useless
And copay accumulator bans continue to spread across the country ... but does it matter?
And I have a survey on what conferences you attend ... I’d be grateful for your input
It's a day of quick hits ... here's to a great weekend
Plus a link to the first-ever ‘Launch Price Communication Report’
And Novo moves to start selling Wegovy directly to patients at $499 a month
And quantifying how the move from copays to coinsurance is driving up OOPs on ‘negotiated’ drugs
And Mesoblast unveils the price for its stem-cell therapy with a noteworthy amount of transparency around value
Plus a couple of links on Elon Musk’s heel turn on health care
But UCB -- bucking the trend -- released its annual numbers: net prices are down, rebates are up
Plus some musings on when or how the 340B debate intersects with legislative pushes around Medicaid
